Dear Editor, Intensive treatments such as autologous stem cell transplantation are standard procedures for lymphoma and myeloma patients. The number of autologous and allogenic procedures available is continuously increasing. To perform these procedures, we need to harvest a sufficient number of circulating marrow stem cells by leukapheresis after stimulation with filgrastim. The collection of peripheral stem cells PBSC is generally a safe procedure, but some patients could present short-or long-term toxicity due to filgrastim stimulation, venous access, or leukapheresis procedure. Here, we present the case of a lymphoma patient, in which the collection of PBSC was followed by a cerebral hemorrhagic event, possibly related to the procedure of apheresis.
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A 58-year-old patient was treated for a diffuse large Bcell lymphoma with anthracyclin-based chemotherapy (Vincristin, Cyclophosphamide, Doxorubicin, and Prednisone) associated to Rituximab, resulting in partial remission. After three courses, the treatment was switched to a platinum-based rescue regimen (Etoposide, Cytarabin, Cisplatin, and Methylprednisolone (ESHAP)) also associated to Rituximab. This type of chemotherapy is frequently associated with grades 3 to 4 hematological toxicity, requiring blood or platelet transfusions. After the third cycle of ESHAP-Rituximab chemotherapy, the patient was stimulated with filgrastim for five consecutive days at a daily dose of approximately 10 µg/kg, in preparation for a peripheral stem cell harvest for an autologous transplantation. Apheresis was performed when the circulating level of CD34 cells was greater than 10 cells per 1 μL of blood. Because the blood count revealed a thrombopenia at 19 giga/L, the patient underwent a platelet transfusion before starting aphaeresis. Three aphaeresis procedures in three consecutive days were necessary to obtain a sufficient graft. During apheresis, patient blood pressure was stable at 120-140 mmHg, and pulse was normal.
The evening following the last apheresis, the patient was hospitalized in the emergency unit for disorientation, aphasia, headache, and vomiting. The patient was negative for recent head injury. Computed tomography found the presence of a subdural hematoma in the temporoparietal right region. Upon hematoma detection, the blood count results were as follows: Hemoglobin 10.2 g/dL, Platelets 43 giga/L, WBC 31 giga/L. The coagulation test had the following results: TP 13.2/13.7 s; ratio 93%, TCA 34/30 s; ratio 0.88. It was decided that surgery was not needed. A new computed tomography performed 36 h later revealed amelioration of the hematoma, and the patient continued his therapeutic program.
Over the past decade, there has been an increasing number of autologous stem cell transplantations performed because these procedures became the standard therapeutic approach for myeloma and lymphoma [1, 2] . There are also an increasing number of allogenic procedures using peripheral stem cells [3] . Leukapheresis procedures after intense cytokine stimulation are generally safe procedures [4] . There are some studies, mainly in volunteer healthy donors, which described the adverse events of leukapheresis. Short-term toxicities occurred as local reactions due to filgrastim administration, complications associated with central venous catheterization, and/or problems with leukapheresis, including bleeding secondary to anticoagulation and hypocalcemia due to acid citrate dextrose use as well as hypotension [5] . Long-term toxicity, while extremely rare, could include toxic death or hematological malignancies [6] .
For our patient, the intense stimulation, resulting in high levels of WBC associated with chemotherapy-induced thrombopenia, was complicated by a cerebral hemorrhage. In our experience, this case is the first reported cerebral hemorrhagic complication potentially due to stem cell harvesting. This complication was rapidly regressive; thus, the patient could continue his therapeutic program.
